Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma

By sjmartinez • September 12, 2022

Haber PK, Castet F, Torres-Martin M, Andreu-Oller C, Puigvehí M, Maeda M, Radu P, Dufour JF, Verslype C, Czauderna C, Marquardt JU, Galle PR, Vogel A, Bathon M, Meyer T, Labgaa I, Digklia A, Roberts LR, Mohamed Ali MA, Mínguez B, Citterio D, Mazzaferro V, Finkelmeier F, Trojan J, Özdirik B, Müller T, Schmelzle M, Bejjani A, Sung MW, Schwartz ME, Finn RS, Thung S, Villanueva A, Sia D, Llovet JM. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology. 2022 Sep 12:S0016-5085(22)01039-3. doi: 10.1053/j.gastro.2022.09.005. Epub ahead of print. PMID: 36108710.

Tags: biomarkers, Hematology/Oncology, Hepatocellular carcinoma, immunotherapy, predictors of response, Publications

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]

Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT)

Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin[...]

Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates

Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative[...]